Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TLR3 signaling does not affect organ-specific immune responses to factor IX in AAV gene therapy.

Literature DB >> 18650463

TLR3 signaling does not affect organ-specific immune responses to factor IX in AAV gene therapy.

Ou Cao, Roland W Herzog.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2008 PMID： 18650463 PMCID： PMC2962552 DOI： 10.1182/blood-2008-02-137992

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

10 in total

1. Systemic protein delivery by muscle-gene transfer is limited by a local immune response.

Authors: Lixin Wang; Eric Dobrzynski; Alexander Schlachterman; Ou Cao; Roland W Herzog
Journal: Blood Date: 2005-02-15 Impact factor: 22.113

2. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

Authors: Karl S Lang; Panco Georgiev; Mike Recher; Alexander A Navarini; Andreas Bergthaler; Mathias Heikenwalder; Nicola L Harris; Tobias Junt; Bernhard Odermatt; Pierre-Alain Clavien; Hanspeter Pircher; Shizuo Akira; Hans Hengartner; Rolf M Zinkernagel
Journal: J Clin Invest Date: 2006-09 Impact factor: 14.808

3. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Authors: Ou Cao; Eric Dobrzynski; Lixin Wang; Sushrusha Nayak; Bethany Mingle; Cox Terhorst; Roland W Herzog
Journal: Blood Date: 2007-04-16 Impact factor: 22.113

Review 4. Tolerance induction by viral in vivo gene transfer.

Authors: Eric Dobrzynski; Roland W Herzog
Journal: Clin Med Res Date: 2005-11

5. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands.

Authors: Bettina Schreiner; Joachim Voss; Jörg Wischhusen; Yvonne Dombrowski; Alexander Steinle; Hanns Lochmüller; Marinos Dalakas; Arthur Melms; Heinz Wiendl
Journal: FASEB J Date: 2005-11-17 Impact factor: 5.191

6. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.

Authors: L Wang; O Cao; B Swalm; E Dobrzynski; F Mingozzi; R W Herzog
Journal: Gene Ther Date: 2005-10 Impact factor: 5.250

7. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.

Authors: A C Nathwani; A Davidoff; H Hanawa; J F Zhou; E F Vanin; A W Nienhuis
Journal: Blood Date: 2001-03-01 Impact factor: 22.113

8. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors: L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal: Nature Date: 2001-10-18 Impact factor: 49.962

9. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors: Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal: Blood Date: 2002-12-19 Impact factor: 22.113

10. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors: Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal: Nat Med Date: 2006-02-12 Impact factor: 53.440

10 in total

5 in total

TLR3 signaling does not affect organ-specific immune responses to factor IX in AAV gene therapy.

1. Systemic protein delivery by muscle-gene transfer is limited by a local immune response.

2. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.

3. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Review 4. Tolerance induction by viral in vivo gene transfer.

5. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands.

6. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.

7. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.

8. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

9. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

10. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

1. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells.

Review 2. Hepatic gene transfer as a means of tolerance induction to transgene products.

Review 3. Evading the immune response upon in vivo gene therapy with viral vectors.

4. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.

5. Innate Immune Responses to AAV Vectors.